Rheumatology Therapeutics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

08/mar/2018 12:34:59 pbi Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Rheumatology Therapeutics Market: By Drug Class (Disease Modifying Anti Rheumatic Drugs (Synthetic, Biologic), Non Steroidal Anti Inflammatory Drugs (NSAID’s), Corticosteroids, Others), By Disorder (Rheumatoid Arthritis, Gout, Ankylosing Spondylitis, Osteo Arthritis, Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023 


Market Outline: Global Rheumatology Therapeutics Market


Rheumatology is the branch of medicine devoted to diagnosis and treatment of the rheumatic diseases. Rheumatology diseases mainly affect the connecting and supporting parts of the body such as ligaments, joints, muscles, tendons and rarely some organs of the body.There are more than 100 types of rheumatic diseases are present but more common are psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis and others. Rheumatology diseases can be caused by various factors such as change in lifestyle, aging, unhealthy food and even genetic factors. The treatment is generally given with disease modifying anti rheumatic drugs and other drugs may be used to decrease the symptoms.


Market dynamics: Global Rheumatology Therapeutics Market


Continuous growth in aging population, rise in prevalence of the diseases such as rheumatoid arthritis, ankylosing spondylitis and increase in R&D activities by the companies to develop new rheumatology therapeutics projected as primary drivers for the global rheumatology therapeutics market. In addition, rise in awareness related to symptoms and treatment of rheumatological disorders coupled with the recent product launches are expected to bolster the market growth over the forecast period. However, availability of the biosimilars, and patent expiry of some drugs is expected to hamper the global rheumatology therapeutics market during the coming years.


A sample of this report is available upon request @





Market Scope: Global Rheumatology Therapeutics Market


Global rheumatology therapeutics market is segmented based on test type, end user, and region

Based on class of drug, market is segmented into

·         Disease Modifying Anti Rheumatic Drugs

o    Synthetic

o    Biologic

·         Non Steroidal Anti Inflammatory Drugs (NSAID’s)

·         Corticosteroids

·         Others


Based on disorder, market is segmented into

·         Rheumatoid Arthritis

·         Gout

·         Ankylosing Spondylitis

·         Osteo Arthritis

·         Others


Based on route of administration, market is segmented into

·         Oral

·         Parenteral

·         Topical


Based on distribution channel, market is segmented into

·         Hospital Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

Based on region, market is segmented into

·         North America

·         Latin America

·         Asia Pacific

·         The Middle East and Africa

·         Europe

Market Summary: Global Rheumatology Therapeutics Market


The market is highly competitive due to the presence of the strong market players involving in development of new rheumatology therapeutics. Companies are developing the novel drugs and expanding the therapeutic applications of existing drugs. For instance, in January 2016, Novartis AG has got two U.S. Food and Drug Administration approvals for its County to treat ankylosing spondylitis and psoriatic arthritis in U.S. in May 2017, Sanofi S.A. has got U.S. Food and Drug Administration approval for its kevazara (sarilumab) to treat active rheumatoid arthritis. Furthermore, companies also focusing on inorganic growth through acquisitions and mergers. For instance, in April 2016, Bristol Myers Squib acquired the Padlock Therapeutics Inc. along with the pipeline of rheumatoid arthritis and autoimmune drug pipeline to strengthen their market position.


To view TOC of this report is available upon request @




Regional Analysis: Global Rheumatology Therapeutics Market


Geographically rheumatology therapeutics market is divided into five key regions, i.e. Europe, North America, Latin America, Asia- Pacific, and The Middle East & Africa. North America rheumatoid arthritis market is expected to grow at significant rates owing to rise in prevalence of the rheumatoid disorders coupled with the recent product launches and established healthcare infrastructure. According to Centre for Disease Control and Prevention, in U.S. adult population by the year of 2040, the prevalence of doctor-diagnosed arthritis will reach to 78.4 million compared with 54.4 million in 2013 to 2015. Asia Pacific rheumatology therapeutics market is expected to have lucrative growth opportunity owing to the prevalence of disease, developed healthcare infrastructure and expansion of global players into emerging Asian countries such as India and China. Europe rheumatology therapeutics market projected to have significant growth rate owing to the rise in aging population, well established healthcare infrastructure and increase in disposable income.



Need more information about this report @



Competition Assessment: Global Rheumatology Therapeutics Market


Some of the players in global rheumatology therapeutics market include

·         AbbVie, Inc. (U.S.)

·         Pfizer Inc. (U.S.)

·         Bristol-Myers Squibb (U.S.)

·         Merck & Co. (U.S.)

·         Amgen, Inc. (U.S.)

·         Janssen Biotech, Inc. (Johnson & Johnson)

·         Novartis AG (Switzerland)

·         Genentech, Inc. (U.S.)

·         Sanofi S.A. (France)

·         Takeda Pharmaceutical (Japan)

·         Celgene Corporation (U.S.)

·         Flexion Therapeutics, Inc. (U.S.)

Notable Market Developments: Global Rheumatology Therapeutics Market


·         In October 2017, Flexion Therapeutics, Inc. got U.S. Food and Drug Administration for its Zilretta, sustained release intraarticular injection to treat osteoarthritis


·         In September 2014, U.S. Food and Drug Administration approved OTEZLA (apermilast), oral selective PDE4 inhibitor to treat moderate to severe plaque psoriasis and symptoms of psoriatic arthritis.


Key Features of the Report:

·         The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)

·         The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies

·         The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market

·         The report tracks recent innovations, key developments and startup’s details that are actively working in the market

·         The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

·         The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market


Get access to full summary @


blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl